Takeda Pharmaceutical (NYSE:TAK) Sets New 52-Week High - Should You Buy?

Shares of Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $15.43 and last traded at $15.37, with a volume of 253486 shares traded. The stock had previously closed at $15.10.

Analysts Set New Price Targets

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.52 and a current ratio of 1.01. The stock's fifty day moving average price is $14.84 and its two-hundred day moving average price is $14.27. The company has a market cap of $49.08 billion, a P/E ratio of 70.12 and a beta of 0.23.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 10.64% and a net margin of 2.36%. The firm had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. As a group, equities analysts predict that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TAK. FNY Investment Advisers LLC purchased a new position in shares of Takeda Pharmaceutical in the first quarter worth about $37,000. Farther Finance Advisors LLC boosted its position in shares of Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after purchasing an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. bought a new position in Takeda Pharmaceutical in the 4th quarter worth about $52,000. Lindbrook Capital LLC boosted its stake in Takeda Pharmaceutical by 65.0% during the 4th quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock valued at $68,000 after purchasing an additional 2,029 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Takeda Pharmaceutical by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company's stock valued at $69,000 after acquiring an additional 1,770 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.